Paperonium

Malaria vaccines · Lancet · 2021

The summary puts group 1’s protection at 77%, above the 75% goal. The results say 71%.

The summary: group 167% to 84%The results: group 2, identicalThe results: group 159% to 79%77%71%−15 points−10−50510the WHO’s 75% goalbelow the goalabove the goal
The summary:group 167% to 84%The results:group 2, identicalThe results:group 159% to 79%77%71%−20−10010the WHO’s 75% goalpointsbelow the goalabove the goal

Percentage points above or below the 75% goal at one year, with likely ranges

The paper says

Children got a malaria vaccine plus an immune-boosting ingredient: group 1 a smaller amount, group 2 twice as much; group 3, for comparison, rabies shots. The World Health Organization’s goal is 75% protection. The paper’s summary says group 1 was 77% protected after one year.

Its own data show

The paper’s results section and its table both put group 1 at 71% after one year, likely range 59% to 79%. The summary’s 77%, range 67% to 84%, is exactly group 2’s one-year result there. Group 1’s other protection figures, at six months or counted other ways, run from 70% to 75%; none is 77%.

77% protection means vaccinated children fell ill with malaria at 23% of the rabies-shot children’s rate. Many readers see only the summary, whose 77% puts group 1 above the 75% goal. The results put it below, at 71%, though its range (59% to 79%) still reaches the goal. The paper’s conclusions claim the goal only for group 2.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial · Lancet (2021) · doi:10.1016/S0140-6736(21)00943-0